# Experimental Study: The Development of a Novel Treatment for Chemotherapy-Resistant Tongue Cancer with the Inhibition of the Pathological Periostin Splicing Variant 1-2 with Exon 21

**Authors:** Shoji Ikebe, Nobutaka Koibuchi, Kana Shibata, Fumihiro Sanada, Hideo Shimizu, Toshihiko Takenobu, Yoshiaki Taniyama

PMC · DOI: 10.3390/cells13161341 · Cells · 2024-08-13

## TL;DR

This study explores a new treatment for tongue cancer by targeting a specific protein variant that contributes to chemotherapy resistance.

## Contribution

The study introduces a novel treatment using an antibody against a specific periostin splicing variant in tongue cancer.

## Key findings

- PN2 increased cell viability and induced chemotherapy resistance in TSCC cells.
- PN1-2 expression in tumor stroma correlated with cancer malignancy.
- Combining PN21-Ab with chemotherapy inhibited tumor growth in a xenograft model.

## Abstract

Tongue squamous cell carcinoma (TSCC) occurs frequently in the oral cavity, and because of its high proliferative and metastatic potential, it is necessary to develop a novel treatment for it. We have reported the importance of the inhibition of the periostin (POSTN) pathological splicing variant, including exon 21 (PN1-2), in various malignancies, but its influence is unclear in tongue cancer. In this study, we investigated the potential of POSTN exon 21-specific neutralizing antibody (PN21-Ab) as a novel treatment for TSCC. Human PN2 was transfected into the human TSCC (HSC-3) and cultured under stress, and PN2 was found to increase cell viability. PN2 induced chemotherapy resistance in HSC-3 via the phosphorylation of the cell survival signal Akt. In tissues from human TSCC and primary tumors of an HSC-3 xenograft model, PN1-2 was expressed in the tumor stroma, mainly from fibroblasts. The intensity of PN1-2 mRNA expression was positively correlated with malignancy. In the HSC-3 xenograft model, CDDP and PN21-Ab promoted CDPP’s inhibition of tumor growth. These results suggest that POSTN exon 21 may be a biomarker for tongue cancer and that PN21-Ab may be a novel treatment for chemotherapy-resistant tongue cancer. The treatment points towards important innovations for TSCC, but many more studies are needed to extrapolate the results.

## Linked entities

- **Genes:** POSTN (periostin) [NCBI Gene 10631]
- **Proteins:** postn (periostin, osteoblast specific factor), AKT1 (AKT serine/threonine kinase 1)
- **Chemicals:** CDDP (PubChem CID 5460033)
- **Diseases:** tongue squamous cell carcinoma (MONDO:0000500), tongue cancer (MONDO:0004631)
- **Species:** Homo sapiens (taxon 9606), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}
- **Diseases:** TSCC (MESH:D000077195), malignancies (MESH:D009369), Tongue Cancer (MESH:D014062)
- **Chemicals:** CDDP (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HSC-3 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_1288)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11353054/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11353054/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC11353054/full.md

---
Source: https://tomesphere.com/paper/PMC11353054